<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489968</url>
  </required_header>
  <id_info>
    <org_study_id>1275.13</org_study_id>
    <nct_id>NCT02489968</nct_id>
  </id_info>
  <brief_title>Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase III, Randomised, Double-blind, Parallel Group, 24-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 10 mg Plus Placebo and a 52-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 25 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 25 mg Plus Placebo in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16-week Treatment With Empagliflozin (10 mg or 25 mg) Alone Once Daily.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will
      evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg +
      linagliptin. All analyses will be carried out separately for these study parts. The objective
      of Part A is to investigate the efficacy, safety and tolerability of the fixed dose
      combination (FDC) of empagliflozin 10 mg / linagliptin 5 mg compared with empagliflozin 10 mg
      plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients
      with T2DM who have insufficient glycaemic control after 16 weeks of treatment with
      empagliflozin 10 mg alone once daily. The study is designed to show superiority of the FDC of
      empagliflozin 10 mg / linagliptin 5 mg over empagliflozin 10 mg plus FDC matching placebo
      after 24 weeks of treatment. The objective of Part B is to investigate the efficacy, safety
      and tolerability of the FDC of empagliflozin 25 mg / linagliptin 5 mg compared with
      empagliflozin 25 mg plus FDC matching placebo administered orally once daily for 24 weeks in
      Japanese patients with T2DM who have insufficient glycaemic control after 16 weeks of
      treatment with empagliflozin 25 mg alone once daily. The study is designed to show
      superiority of the FDC of empagliflozin 25 mg / linagliptin 5 mg over empagliflozin 25 mg
      plus FDC matching placebo after 24 weeks of treatment. The 24 week treatment period will be
      followed by a 28 week extension treatment period to evaluate further efficacy and safety up
      to 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2015</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">November 18, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in HbA1c from baseline (Visit 5) after 24 weeks of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">889</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>empagliflozin 10 mg + linagliptin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing low dose empagliflozin and linagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing low dose empagliflozin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 25 mg + linagliptin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing high dose empagliflozin and linagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients to receive a tablet containing high dose empagliflozin once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 10 mg + linagliptin 5 mg</intervention_name>
    <description>empagliflozin low dose + linagliptin once daily</description>
    <arm_group_label>empagliflozin 10 mg + linagliptin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 10 mg</intervention_name>
    <description>empagliflozin low dose once daily</description>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 25 mg + linagliptin 5 mg</intervention_name>
    <description>empagliflozin high dose + linagliptin once daily</description>
    <arm_group_label>empagliflozin 25 mg + linagliptin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 25 mg</intervention_name>
    <description>empagliflozin high dose once daily</description>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of type 2 diabetes prior to informed consent

          -  Male and female patients on diet and exercise regimen for at least 12 weeks prior to
             informed consent who are:

               -  drug-na√Øve, defined as no antidiabetic drugs for at least 12 weeks prior to
                  informed consent or,

               -  pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of
                  the maximum approved dose) on stable dosage for at least 12 weeks prior to the
                  informed consent (for thiazolidinedione, therapy has to be unchanged for at least
                  18 weeks prior to the informed consent). Individual antidiabetic drug will have
                  to be discontinued at Visit 1.

          -  haemoglobin A1c (HbA1c) at Visit 1 (screening)

               -  for patients without antidiabetic therapy : HbA1c &gt;=8.0 to =&lt;10.5%

               -  for patients with one oral antidiabetic drug : HbA1c &gt;=7.5 to =&lt;10.5%

          -  HbA1c &gt;=7.5 to =&lt;10.0% at Visit 4 for randomisation into the double blind treatment
             period

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt;270 mg/dL (&gt;15.0 mmol/L) during the
             open label stabilisation period and placebo run in period

          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) &lt;45
             mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1275.13.81078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Kasugai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ehime, Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ehime, Niihama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ehime, Saijo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Onga-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Yukuhashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifu, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gunma, Maebashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Chitose</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Ebetsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Hakodate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Hakodate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Ashiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Koga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Namegata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ishikawa, Kanazawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwate, Morioka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwate, Morioka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagawa, Zentsuji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Chigasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Kamakura</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagano, Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagano, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niigata, Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Tsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Naha</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Tomigusuku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Suita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saga, Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Koshigaya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Okegawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Sakado</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Tokorozawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tochigi, Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Edogawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Katushika-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Kiyose</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Nerima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Ota-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Ota-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyama, Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.13.81082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamagata, Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 16, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

